Cellife COVID-19 / Flu A / Flu B / RSV / ADV / HMPV (6-in-1) (TGA Pending)

Cellife 6 in 1 Respiratory Antigen Test

The Cellife 6 in 1 is a rapid self-test designed to qualitatively detect Influenza A, Influenza B, COVID-19, HMPV, RSV, and Adenovirus antigens from a nasal swab sample.

This easy-to-use combo test is intended for self-testing and delivers results in as little as 10–15 minutes.

Key Features

• Tests for 6 common respiratory viruses in one cassette
• Nasal swab sample collection
• Fast results in 10–15 minutes
• Designed for self-testing
• Clear result interpretation with built-in control line

What it detects

• Influenza A
• Influenza B
• COVID-19
• HMPV (Human Metapneumovirus)
• RSV (Respiratory Syncytial Virus)
• Adenovirus

How to use

1. Collect the nasal swab sample as instructed.
2. Insert the swab into the extraction tube and mix thoroughly.
3. Add the processed sample into the test cassette.
4. Read results after 10–15 minutes.

Important: Do not read results after 15 minutes. A visible control line is required for a valid result.

Instruction Video

Watch instruction video

Instructions for Use

View full Instructions for Use (PDF)

Intended Use

Flu A/B+COVID-19/HMPV+RSV/Adeno Antigen Combo Test Cassette (Nasal Swab) is an immunochromatographic test intended for the qualitative detection of influenza A virus, influenza B virus, SARS-CoV-2, human metapneumovirus (HMPV), respiratory syncytial virus (RSV), and adenovirus antigens in nasal swab specimens. The test is intended to be performed by laypersons as a self-testing rapid test to aid in detection of infection in individuals suspected of infection with SARS-CoV-2 (COVID-19) within the first 7 days of symptom onset, and Influenza A/B, HMPV, RSV, or adenovirus within the first 4 days of symptom onset. The device is intended as an aid for diagnosis, not as a standalone diagnostic tool.

Important Information

• For in vitro diagnostic self-testing use only.
• Follow all instructions carefully before use.
• A negative result does not rule out infection.
• If symptoms persist, repeat testing and seek medical advice.
• If the control line does not appear, the result is invalid and the test should be repeated.

Performance Characteristics

Clinical performance of the Cellife 6 in 1 test has been evaluated against nucleic acid (PCR) reference methods, demonstrating a high level of agreement.

• Relative Sensitivity: approximately 90–97% (varies by pathogen)
• Relative Specificity: approximately 99.9–100%
• Total Agreement: approximately 97–99%

Test performance may vary depending on viral load and stage of infection. Lower antigen levels may produce weaker test lines.

Adverse Event Reporting:
If you experience poor performance or usability issues, report the incident via the Therapeutic Goods Administration (TGA):
Phone: 1800 809 361
Email: iris@health.gov.au